For his final "Executive Decision" segment of Tuesday's Mad Money program, Jim Cramer checked in with Dr. Vlad Coric, CEO of Biohaven Pharmaceuticals (BHVN) , which on Tuesday received FDA approval to use its drug Nurtec ODT for the prevention of migraine.
Coric said they've been working for years to get to today, where they can offer patients one pill for both the treatment and prevention of migraine.
Coric added that prevention is critically important because most patients know what their triggers are and know when migraine is about to hit. Now, instead of suffering, they can simply take one pill to safely and effectively stop the event before it even starts.
Biohaven is working on a lot more than just migraine treatments, Coric added. He said his company has vast expertise in lots of neurological conditions, and while it won't find treatments for all of them, he's confident that more drugs like Nurtec ODT are in its future.